Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney ...
Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a takeover of US health products manufacturer Catalent, in a deal worth $11. ...
The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback